Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases

Eddy Owaga, Rong Hong Hsieh, Beatrice Mugendi, Sakhile Masuku, Chun Kuang Shih, Jung Su Chang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A-F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.

Original languageEnglish
Pages (from-to)20841-20858
Number of pages18
JournalInternational Journal of Molecular Sciences
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Th17 Cells
Probiotics
Inflammatory Bowel Diseases
cells
pathogenesis
Therapeutics
Cytokines
Interleukin-17
plants (botany)
Insurance Benefits
interleukins
immune systems
Ulcerative Colitis
Crohn Disease
Autoimmune Diseases
Immune system
Cell Differentiation
Immune System
microorganisms
mounting

Keywords

  • IL-17
  • Inflammation
  • Inflammatory bowel diseases
  • Probiotics
  • Th17

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Spectroscopy
  • Inorganic Chemistry
  • Catalysis
  • Molecular Biology
  • Computer Science Applications

Cite this

Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. / Owaga, Eddy; Hsieh, Rong Hong; Mugendi, Beatrice; Masuku, Sakhile; Shih, Chun Kuang; Chang, Jung Su.

In: International Journal of Molecular Sciences, Vol. 16, No. 9, 01.09.2015, p. 20841-20858.

Research output: Contribution to journalArticle

@article{4e14468622674876b2ca4ef22f42ad1b,
title = "Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases",
abstract = "Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A-F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.",
keywords = "IL-17, Inflammation, Inflammatory bowel diseases, Probiotics, Th17",
author = "Eddy Owaga and Hsieh, {Rong Hong} and Beatrice Mugendi and Sakhile Masuku and Shih, {Chun Kuang} and Chang, {Jung Su}",
year = "2015",
month = "9",
day = "1",
doi = "10.3390/ijms160920841",
language = "English",
volume = "16",
pages = "20841--20858",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "9",

}

TY - JOUR

T1 - Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases

AU - Owaga, Eddy

AU - Hsieh, Rong Hong

AU - Mugendi, Beatrice

AU - Masuku, Sakhile

AU - Shih, Chun Kuang

AU - Chang, Jung Su

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A-F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.

AB - Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A-F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.

KW - IL-17

KW - Inflammation

KW - Inflammatory bowel diseases

KW - Probiotics

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=84940843952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940843952&partnerID=8YFLogxK

U2 - 10.3390/ijms160920841

DO - 10.3390/ijms160920841

M3 - Article

C2 - 26340622

AN - SCOPUS:84940843952

VL - 16

SP - 20841

EP - 20858

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

ER -